Understanding organ dysfunction in Ebola virus disease

Intensive Care Medicine

Volumn 40, Issue 12, 2014, Pages 1936-1939

  Fletcher, Tom E ^a   Fowler, Robert A ^b   Beeching, Nicholas J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CD40 LIGAND; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; APOPTOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CAPILLARY LEAK SYNDROME; CHEMICAL INDUSTRY; CHRONIC KIDNEY FAILURE; CYTOKINE PRODUCTION; DIARRHEA; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FEVER; FULMINANT HEPATIC FAILURE; HEADACHE; HEMATEMESIS; HEMORRHAGIC SHOCK; HUMAN; HYPERVENTILATION; HYPOVOLEMIA; INFLAMMATION; KIDNEY DYSFUNCTION; LETHARGY; LEUKOPENIA; LIVER NECROSIS; LUNG INJURY; MELENA; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VIRUS PATHOGENESIS; VOMITING; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; PATHOGENICITY; VIROLOGY;

EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MULTIPLE ORGAN FAILURE;

EID: 84918791922     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3515-1     Document Type: Article

References (20)

1. Leroy EM, Gonzalez J-P, Baize S (2011) Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 17:964–976. doi:10.1111/j.1469-0691.2011.03535.x
2. Feldmann H, Geisbert TW (2011) Ebola haemorrhagic fever. Lancet 377:849–862. doi:10.1016/S0140-6736(10)60667-8
3. WHO Ebola Response Team (2014) Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med. 371:1481–1495. doi:10.1056/NEJMoa1411100
4. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885–891
5. Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851. doi:10.1056/NEJMra1208623
6. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Med 39(2):165–228. doi:10.1007/s00134-012-2769-8
7. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropolou CF (2014) Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis 210(4):558–566. doi:10.1093/infdis/jiu088
8. Bente D, Gren J, Strong JE, Feldmann H (2009) Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2:12–17. doi:10.1242/dmm.000471
9. Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and challenges. Nature Med 10(Suppl 12):S110–121. doi:10.1038/nm1142
10. Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4(8):487–498
11. Mohamadzadeh M, Chen L, Schmaljohn AL (2007) How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 7:556–567. doi:10.1038/nri2098
12. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163:2371–2382
13. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ (1999) Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179(Suppl 1):S188–191. doi:10.1086/514283
14. Hensley LE, Young HA, Jahrling PB, Geisbert TW (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80:169–179. doi:10.1016/s0165-2478(01)00327-3
15. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW (2004) Depletion of peripheral blood T lymphocytes and NK cells during the course of ebolahemorrhagic fever in cynomolgus macaques. Viral Immunol 17:390–400. doi:10.1089/vim.2004.17.390
16. Leblebicioglu H, Bodur H, Dokuzoguz B, Elaldi N, Guner R, Koksal I, Kurt H, Senturk GC (2012) Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 12:805–811. doi:10.1089/vbz.2011.0896
17. Rollin PE, Bausch DG, Sanchez A (2007) Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola Virus. J Infect Dis 196(Suppl 2):S364–371
18. Mupere E, Kaducu OF, Yoti Z (2001) Ebola haemorrhagic fever among hospitalised children and adolescents in nothern Uganda: epidemiologic and clinical observations. Afr Hlth Sci 1(2): 60–65. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2141551/
19. Goodman JL (2014) Studying “Secret Serums”—toward safe, effective Ebola treatments. N Engl J Med 371:108–1089. doi:10.1056/NEJMp1409817
20. Fowler RA, Fletcher T, Fischer WA, Lamontagne F, Jacob S, Brett-Major D et al (2014) Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 190(7):733–737